Body composition and weight gain in new users of the three-monthly injectable contraceptive, depot-medroxyprogesterone acetate, after 12 months of follow-up

Autor(es)

Silva dos Santos, Priscilla de Nazare ^[1] ; Modesto, Waleska Oliveira ^[1] ; Dal'Ava, Nathalia ^[1] ; Bahamondes, Maria Valeria ^[1] ; Pavin, Elizabeth Joao ^[2] ; Fernandes, Arlete ^[1]

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP - Brazil

^[2] Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Med, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. 19, n. 6, p. 432-438, DEC 2014.
• Citações Web of Science: 6

Resumo

Objectives To evaluate weight gain and body composition (BC) in new users of depot-medroxyprogesterone acetate (DMPA) as a contraceptive. Methods This cohort study followed up 20 DMPA users and 20 copper intrauterine device (TCu380A IUD) users, paired for age (+/- 1 year) and body mass index (BMI +/- 1 kg/m 2), during 12-months. Healthy, non-obese women aged 18 to 40 years, unaffected by conditions that could influence their body weight, were enrolled. Socio-demographic variables, habits, weight, BMI, BC using dual-energy X-ray absorptiometry, circumferences, skinfold thickness, body fat percentage and waist-to-hip ratio were evaluated. All participants were encouraged to adopt healthy habits. Results At baseline, median age was 29 and 30.5 years, and mean BMI was 24.8 and 24.5 kg/m 2 in the DMPA and IUD groups, respectively. At 12 months, an increase was observed in waist and hip circumference in the DMPA users and 8/20 of them had a weight gain >= 5% (mean 4.6 kg) with accumulation of fat centrally. Conclusions There were no differences in weight gain or in BC measurements between the groups; nevertheless 40% of women in the DMPA group had larger weight gain and accumulation of fat centrally. The duration of follow-up may have been insuffi cient to detect differences between the groups. (AU)

• Processo FAPESP: 09/53293-0 - Estudo prospectivo de avaliação da resistência insulínica, metabolismo de lípedes e repercussão subclínica de doença cardiovascular em mulheres que iniciam o uso do contraceptivo injetável trimestal de acetato de medroxiprogesterona de depósito em segmento de 2 anos
• Beneficiário: Luis Guillermo Bahamondes
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa em Políticas Públicas para o SUS